Optimizing Clinical Outcomes in Blood Cancers







Jointly provided by The Leukemia & Lymphoma Society, RMEI Medical Education, LLC, and Postgraduate Institute for Medicine.

The educational portion of this activity is supported by independent educational grants from Amgen Inc., AstraZeneca Pharmaceuticals LP, and Bristol-Myers Squibb Company. Additional funding provided by The Leukemia & Lymphoma Society.

Specialty: Hematology, Oncology

Activity Purpose: This activity will provide learners with the latest developments in translational medicine for leukemia, lymphoma, and myeloma and how these developments can be incorporated into regimens to improve the outcome of patients with these diseases.

Target Audience: This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Estimated Time to Complete Activities: 30 minutes for Module 1; 45 minutes for Modules 2 & 3; 30 minutes for Module 4; 75 minutes for Module 5



Cheryl L. Willman, MD (Chair)
The Maurice & Marguerite Liberman Distinguished Endowed Chair in Cancer Research
UNM Distinguished Professor of Pathology, UNM School of Medicine
Director & CEO
University of New Mexico Comprehensive Cancer Center
Albuquerque, NM



Philippe Armand, MD, PhD
Harold and Virginia Lash/David Lash Chair in Lymphoma Research
Chief, Lymphoma Division
Dana-Farber Cancer Institute
Boston, MA



Catherine M. Bollard, MD, FRACP, FRCPA
Bosworth Chair for Cancer Biology
Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine
Director, Center for Cancer and Immunology Research
Director, Program for Cell Enhancement and Technologies for Immunotherapy
Children’s National Health System
The George Washington University School of Medicine and Health Sciences
Washington, DC



Benjamin L. Ebert, MD, PhD
George P. Canellos, MD and Jean S. Canellos Professor of Medicine
Harvard Medical School
Chair, Department of Medical Oncology
Dana-Farber Cancer Institute, Boston, MA
Investigator, Howard Hughes Medical Institute


Stephen P. Hunger, MD
Chief, Division of Oncology
Director, Center for Childhood Cancer Research
Jeffrey E. Perelman Distinguished Chair, Department of Pediatrics
Children’s Hospital of Philadelphia
Professor, Department of Pediatrics
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA


C. Ola Landgren, MD, PhD
Professor, Medicine
Chief, Myeloma Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY